Kolte-Patil Developers Limited
Kolte-Patil Developers Limited (KOLTEPATIL.BO) Stock Competitors & Peer Comparison
See (KOLTEPATIL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Real Estate - Development Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KOLTEPATIL.BO | ₹395.35 | +3.68% | 34.5B | 66.27 | ₹5.87 | N/A |
| DLF.NS | ₹607.20 | +2.14% | 1.5T | 32.82 | ₹17.89 | +1.02% |
| DLF.BO | ₹607.15 | +2.21% | 1.5T | 32.80 | ₹17.90 | +1.02% |
| LODHA.BO | ₹923.55 | +1.12% | 896.7B | 26.21 | ₹34.25 | +0.48% |
| LODHA.NS | ₹923.60 | +1.19% | 892.6B | 26.10 | ₹34.23 | +0.48% |
| OBEROIRLTY.BO | ₹1,692.00 | -0.31% | 606.8B | 27.09 | ₹61.61 | +0.48% |
| OBEROIRLTY.NS | ₹1,693.70 | -0.39% | 606.8B | 27.11 | ₹61.55 | +0.48% |
| GODREJPROP.NS | ₹1,899.80 | +2.01% | 551.8B | 34.86 | ₹52.55 | N/A |
| GODREJPROP.BO | ₹1,899.80 | +1.91% | 551.5B | 35.51 | ₹51.57 | N/A |
| BRIGADE.NS | ₹791.50 | -0.75% | 192.3B | 25.70 | ₹30.60 | +0.32% |
Stock Comparison
KOLTEPATIL.BO vs DLF.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, DLF.NS has a market cap of 1.5T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while DLF.NS trades at ₹607.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas DLF.NS's P/E ratio is 32.82. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DLF.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to DLF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.NS's competition here
KOLTEPATIL.BO vs DLF.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, DLF.BO has a market cap of 1.5T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while DLF.BO trades at ₹607.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas DLF.BO's P/E ratio is 32.80. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DLF.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to DLF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.BO's competition here
KOLTEPATIL.BO vs LODHA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, LODHA.BO has a market cap of 896.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while LODHA.BO trades at ₹923.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas LODHA.BO's P/E ratio is 26.21. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to LODHA.BO's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to LODHA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.BO's competition here
KOLTEPATIL.BO vs LODHA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, LODHA.NS has a market cap of 892.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while LODHA.NS trades at ₹923.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas LODHA.NS's P/E ratio is 26.10. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to LODHA.NS's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to LODHA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.NS's competition here
KOLTEPATIL.BO vs OBEROIRLTY.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OBEROIRLTY.BO has a market cap of 606.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OBEROIRLTY.BO trades at ₹1,692.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OBEROIRLTY.BO's P/E ratio is 27.09. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OBEROIRLTY.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OBEROIRLTY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.BO's competition here
KOLTEPATIL.BO vs OBEROIRLTY.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OBEROIRLTY.NS has a market cap of 606.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OBEROIRLTY.NS trades at ₹1,693.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OBEROIRLTY.NS's P/E ratio is 27.11. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OBEROIRLTY.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OBEROIRLTY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.NS's competition here
KOLTEPATIL.BO vs GODREJPROP.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GODREJPROP.NS has a market cap of 551.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GODREJPROP.NS trades at ₹1,899.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GODREJPROP.NS's P/E ratio is 34.86. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GODREJPROP.NS's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GODREJPROP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.NS's competition here
KOLTEPATIL.BO vs GODREJPROP.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GODREJPROP.BO has a market cap of 551.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GODREJPROP.BO trades at ₹1,899.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GODREJPROP.BO's P/E ratio is 35.51. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GODREJPROP.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GODREJPROP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.BO's competition here
KOLTEPATIL.BO vs BRIGADE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, BRIGADE.NS has a market cap of 192.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while BRIGADE.NS trades at ₹791.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas BRIGADE.NS's P/E ratio is 25.70. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to BRIGADE.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to BRIGADE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.NS's competition here
KOLTEPATIL.BO vs BRIGADE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, BRIGADE.BO has a market cap of 192.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while BRIGADE.BO trades at ₹792.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas BRIGADE.BO's P/E ratio is 25.71. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to BRIGADE.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to BRIGADE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.BO's competition here
KOLTEPATIL.BO vs ANANTRAJ.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ANANTRAJ.BO has a market cap of 175.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ANANTRAJ.BO trades at ₹510.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ANANTRAJ.BO's P/E ratio is 32.04. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ANANTRAJ.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ANANTRAJ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.BO's competition here
KOLTEPATIL.BO vs ANANTRAJ.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ANANTRAJ.NS has a market cap of 174.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ANANTRAJ.NS trades at ₹510.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ANANTRAJ.NS's P/E ratio is 31.95. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ANANTRAJ.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ANANTRAJ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.NS's competition here
KOLTEPATIL.BO vs SOBHA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SOBHA.NS has a market cap of 153.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SOBHA.NS trades at ₹1,440.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SOBHA.NS's P/E ratio is 107.27. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SOBHA.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SOBHA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.NS's competition here
KOLTEPATIL.BO vs SOBHA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SOBHA.BO has a market cap of 152.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SOBHA.BO trades at ₹1,438.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SOBHA.BO's P/E ratio is 107.09. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SOBHA.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SOBHA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.BO's competition here
KOLTEPATIL.BO vs SIGNATURE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SIGNATURE.BO has a market cap of 121.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SIGNATURE.BO trades at ₹880.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SIGNATURE.BO's P/E ratio is 3332.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SIGNATURE.BO's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SIGNATURE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.BO's competition here
KOLTEPATIL.BO vs SIGNATURE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SIGNATURE.NS has a market cap of 121.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SIGNATURE.NS trades at ₹878.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SIGNATURE.NS's P/E ratio is 3326.54. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SIGNATURE.NS's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SIGNATURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.NS's competition here
KOLTEPATIL.BO vs IBREALEST.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, IBREALEST.BO has a market cap of 95.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while IBREALEST.BO trades at ₹150.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas IBREALEST.BO's P/E ratio is -7.83. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBREALEST.BO's ROE of -0.32%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to IBREALEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.BO's competition here
KOLTEPATIL.BO vs IBREALEST.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, IBREALEST.NS has a market cap of 83.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while IBREALEST.NS trades at ₹131.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas IBREALEST.NS's P/E ratio is -6.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBREALEST.NS's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to IBREALEST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.NS's competition here
KOLTEPATIL.BO vs MAHLIFE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MAHLIFE.BO has a market cap of 72.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MAHLIFE.BO trades at ₹335.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MAHLIFE.BO's P/E ratio is 23.32. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAHLIFE.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MAHLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.BO's competition here
KOLTEPATIL.BO vs MAHLIFE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MAHLIFE.NS has a market cap of 72.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MAHLIFE.NS trades at ₹335.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MAHLIFE.NS's P/E ratio is 23.49. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAHLIFE.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MAHLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.NS's competition here
KOLTEPATIL.BO vs KALPATARU.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, KALPATARU.NS has a market cap of 67.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while KALPATARU.NS trades at ₹326.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas KALPATARU.NS's P/E ratio is -64.87. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KALPATARU.NS's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KALPATARU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KALPATARU.NS's competition here
KOLTEPATIL.BO vs MAXESTATES.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MAXESTATES.BO has a market cap of 64.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MAXESTATES.BO trades at ₹405.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MAXESTATES.BO's P/E ratio is 130.21. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAXESTATES.BO's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MAXESTATES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.BO's competition here
KOLTEPATIL.BO vs MAXESTATES.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MAXESTATES.NS has a market cap of 63.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MAXESTATES.NS trades at ₹405.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MAXESTATES.NS's P/E ratio is 128.75. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAXESTATES.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAXESTATES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.NS's competition here
KOLTEPATIL.BO vs DBREALTY.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, DBREALTY.NS has a market cap of 56.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while DBREALTY.NS trades at ₹124.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas DBREALTY.NS's P/E ratio is 53.30. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DBREALTY.NS's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DBREALTY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.NS's competition here
KOLTEPATIL.BO vs GANESHHOU.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GANESHHOU.BO has a market cap of 55.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GANESHHOU.BO trades at ₹657.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GANESHHOU.BO's P/E ratio is 13.15. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOU.BO's ROE of +0.25%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.BO's competition here
KOLTEPATIL.BO vs GANESHHOUC.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GANESHHOUC.BO has a market cap of 55.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GANESHHOUC.BO trades at ₹656.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GANESHHOUC.BO's P/E ratio is 9.57. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOUC.BO's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOUC.BO's competition here
KOLTEPATIL.BO vs GANESHHOU.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GANESHHOU.NS has a market cap of 55.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GANESHHOU.NS trades at ₹658.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GANESHHOU.NS's P/E ratio is 13.13. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOU.NS's ROE of +0.25%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.NS's competition here
KOLTEPATIL.BO vs DBREALTY.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, DBREALTY.BO has a market cap of 54.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while DBREALTY.BO trades at ₹123.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas DBREALTY.BO's P/E ratio is 51.80. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DBREALTY.BO's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DBREALTY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.BO's competition here
KOLTEPATIL.BO vs NIRLON.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NIRLON.BO has a market cap of 51.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NIRLON.BO trades at ₹570.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NIRLON.BO's P/E ratio is 15.59. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NIRLON.BO's ROE of +0.84%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NIRLON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NIRLON.BO's competition here
KOLTEPATIL.BO vs PURVA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PURVA.BO has a market cap of 50.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PURVA.BO trades at ₹219.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PURVA.BO's P/E ratio is -37.53. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PURVA.BO's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PURVA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.BO's competition here
KOLTEPATIL.BO vs PURVA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PURVA.NS has a market cap of 50.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PURVA.NS trades at ₹219.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PURVA.NS's P/E ratio is -37.53. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PURVA.NS's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to PURVA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.NS's competition here
KOLTEPATIL.BO vs SUNTECK.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SUNTECK.NS has a market cap of 50B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SUNTECK.NS trades at ₹339.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SUNTECK.NS's P/E ratio is 24.46. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUNTECK.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SUNTECK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.NS's competition here
KOLTEPATIL.BO vs SUNTECK.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SUNTECK.BO has a market cap of 50B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SUNTECK.BO trades at ₹338.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SUNTECK.BO's P/E ratio is 24.45. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUNTECK.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SUNTECK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.BO's competition here
KOLTEPATIL.BO vs RUSTOMJEE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RUSTOMJEE.BO has a market cap of 49.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RUSTOMJEE.BO trades at ₹396.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RUSTOMJEE.BO's P/E ratio is 54.78. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RUSTOMJEE.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RUSTOMJEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.BO's competition here
KOLTEPATIL.BO vs RUSTOMJEE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RUSTOMJEE.NS has a market cap of 49.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RUSTOMJEE.NS trades at ₹396.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RUSTOMJEE.NS's P/E ratio is 54.58. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RUSTOMJEE.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RUSTOMJEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.NS's competition here
KOLTEPATIL.BO vs AGIIL.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, AGIIL.NS has a market cap of 49.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while AGIIL.NS trades at ₹407.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas AGIIL.NS's P/E ratio is 57.47. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AGIIL.NS's ROE of +0.27%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.NS's competition here
KOLTEPATIL.BO vs GANESHHOUC.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GANESHHOUC.NS has a market cap of 48.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GANESHHOUC.NS trades at ₹584.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GANESHHOUC.NS's P/E ratio is 8.44. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOUC.NS's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOUC.NS's competition here
KOLTEPATIL.BO vs IBULLSLTD.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, IBULLSLTD.NS has a market cap of 44.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while IBULLSLTD.NS trades at ₹21.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas IBULLSLTD.NS's P/E ratio is -3.30. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBULLSLTD.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.NS's competition here
KOLTEPATIL.BO vs IBULLSLTD.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, IBULLSLTD.BO has a market cap of 44B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while IBULLSLTD.BO trades at ₹21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas IBULLSLTD.BO's P/E ratio is -3.30. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBULLSLTD.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.BO's competition here
KOLTEPATIL.BO vs TARC.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, TARC.BO has a market cap of 39.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while TARC.BO trades at ₹138.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas TARC.BO's P/E ratio is -45.32. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to TARC.BO's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to TARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.BO's competition here
KOLTEPATIL.BO vs TARC.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, TARC.NS has a market cap of 39.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while TARC.NS trades at ₹138.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas TARC.NS's P/E ratio is -45.20. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to TARC.NS's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to TARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.NS's competition here
KOLTEPATIL.BO vs KESAR.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, KESAR.BO has a market cap of 35.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while KESAR.BO trades at ₹1,249.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas KESAR.BO's P/E ratio is 125.46. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KESAR.BO's ROE of +0.28%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to KESAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KESAR.BO's competition here
KOLTEPATIL.BO vs ASHIANA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ASHIANA.BO has a market cap of 34.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ASHIANA.BO trades at ₹347.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ASHIANA.BO's P/E ratio is 28.94. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASHIANA.BO's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ASHIANA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.BO's competition here
KOLTEPATIL.BO vs ASHIANA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ASHIANA.NS has a market cap of 34.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ASHIANA.NS trades at ₹348.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ASHIANA.NS's P/E ratio is 28.88. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASHIANA.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ASHIANA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.NS's competition here
KOLTEPATIL.BO vs KOLTEPATIL.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, KOLTEPATIL.NS has a market cap of 34.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while KOLTEPATIL.NS trades at ₹395.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas KOLTEPATIL.NS's P/E ratio is 65.53. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KOLTEPATIL.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KOLTEPATIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KOLTEPATIL.NS's competition here
KOLTEPATIL.BO vs MARATHON.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MARATHON.NS has a market cap of 31.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MARATHON.NS trades at ₹493.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MARATHON.NS's P/E ratio is 12.87. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MARATHON.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MARATHON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.NS's competition here
KOLTEPATIL.BO vs MARATHON.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MARATHON.BO has a market cap of 31.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MARATHON.BO trades at ₹488.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MARATHON.BO's P/E ratio is 12.86. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MARATHON.BO's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MARATHON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.BO's competition here
KOLTEPATIL.BO vs HUBTOWN.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, HUBTOWN.BO has a market cap of 28.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while HUBTOWN.BO trades at ₹205.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas HUBTOWN.BO's P/E ratio is 22.54. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HUBTOWN.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to HUBTOWN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.BO's competition here
KOLTEPATIL.BO vs HUBTOWN.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, HUBTOWN.NS has a market cap of 28.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while HUBTOWN.NS trades at ₹205.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas HUBTOWN.NS's P/E ratio is 22.45. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HUBTOWN.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to HUBTOWN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.NS's competition here
KOLTEPATIL.BO vs ARVSMART.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARVSMART.BO has a market cap of 28.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARVSMART.BO trades at ₹630.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARVSMART.BO's P/E ratio is 38.98. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARVSMART.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARVSMART.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.BO's competition here
KOLTEPATIL.BO vs ARVSMART.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARVSMART.NS has a market cap of 28.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARVSMART.NS trades at ₹631.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARVSMART.NS's P/E ratio is 38.79. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARVSMART.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ARVSMART.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.NS's competition here
KOLTEPATIL.BO vs NATIONSTD.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NATIONSTD.BO has a market cap of 26.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NATIONSTD.BO trades at ₹1,355.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NATIONSTD.BO's P/E ratio is 273.71. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NATIONSTD.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NATIONSTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NATIONSTD.BO's competition here
KOLTEPATIL.BO vs AJMERA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, AJMERA.BO has a market cap of 24.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while AJMERA.BO trades at ₹126.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas AJMERA.BO's P/E ratio is 18.72. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AJMERA.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to AJMERA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.BO's competition here
KOLTEPATIL.BO vs AJMERA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, AJMERA.NS has a market cap of 24.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while AJMERA.NS trades at ₹126.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas AJMERA.NS's P/E ratio is 18.42. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AJMERA.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to AJMERA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.NS's competition here
KOLTEPATIL.BO vs ALEMBICLTD.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ALEMBICLTD.BO has a market cap of 23.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ALEMBICLTD.BO trades at ₹91.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ALEMBICLTD.BO's P/E ratio is 7.27. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ALEMBICLTD.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ALEMBICLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ALEMBICLTD.BO's competition here
KOLTEPATIL.BO vs ARKADE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARKADE.NS has a market cap of 21.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARKADE.NS trades at ₹126.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARKADE.NS's P/E ratio is 14.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARKADE.NS's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARKADE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARKADE.NS's competition here
KOLTEPATIL.BO vs MIIL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MIIL.BO has a market cap of 16.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MIIL.BO trades at ₹765.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MIIL.BO's P/E ratio is 1979.49. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MIIL.BO's ROE of +0.41%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MIIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MIIL.BO's competition here
KOLTEPATIL.BO vs OMAXE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OMAXE.BO has a market cap of 15.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OMAXE.BO trades at ₹85.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OMAXE.BO's P/E ratio is -2.36. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OMAXE.BO's ROE of +3.05%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OMAXE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.BO's competition here
KOLTEPATIL.BO vs OMAXE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OMAXE.NS has a market cap of 15.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OMAXE.NS trades at ₹85.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OMAXE.NS's P/E ratio is -2.33. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OMAXE.NS's ROE of +3.05%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OMAXE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.NS's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SHRIRAMPPS.NS has a market cap of 14.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SHRIRAMPPS.NS trades at ₹90.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SHRIRAMPPS.NS's P/E ratio is 20.73. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SHRIRAMPPS.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.NS's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SHRIRAMPPS.BO has a market cap of 14.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SHRIRAMPPS.BO trades at ₹90.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SHRIRAMPPS.BO's P/E ratio is 20.69. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SHRIRAMPPS.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.BO's competition here
KOLTEPATIL.BO vs ASL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ASL.BO has a market cap of 12.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ASL.BO trades at ₹310.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ASL.BO's P/E ratio is -1320.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASL.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASL.BO's competition here
KOLTEPATIL.BO vs ARIHANTSUP.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARIHANTSUP.NS has a market cap of 12.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARIHANTSUP.NS trades at ₹270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARIHANTSUP.NS's P/E ratio is 28.04. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANTSUP.NS's ROE of +0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.NS's competition here
KOLTEPATIL.BO vs ARIHANTSUP.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARIHANTSUP.BO has a market cap of 12B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARIHANTSUP.BO trades at ₹267.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARIHANTSUP.BO's P/E ratio is 27.94. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANTSUP.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.BO's competition here
KOLTEPATIL.BO vs SURAJEST.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SURAJEST.NS has a market cap of 11.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SURAJEST.NS trades at ₹234.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SURAJEST.NS's P/E ratio is 12.25. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SURAJEST.NS's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SURAJEST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SURAJEST.NS's competition here
KOLTEPATIL.BO vs AGIIL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, AGIIL.BO has a market cap of 9.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while AGIIL.BO trades at ₹407.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas AGIIL.BO's P/E ratio is 57.54. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AGIIL.BO's ROE of +0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.BO's competition here
KOLTEPATIL.BO vs ARIHANT.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARIHANT.BO has a market cap of 9.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARIHANT.BO trades at ₹922.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARIHANT.BO's P/E ratio is 14.72. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANT.BO's ROE of +0.23%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANT.BO's competition here
KOLTEPATIL.BO vs RDBRIL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RDBRIL.BO has a market cap of 9.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RDBRIL.BO trades at ₹53.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RDBRIL.BO's P/E ratio is 213.12. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RDBRIL.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RDBRIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RDBRIL.BO's competition here
KOLTEPATIL.BO vs MCCHRLS-B.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MCCHRLS-B.BO has a market cap of 9.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MCCHRLS-B.BO trades at ₹690.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MCCHRLS-B.BO's P/E ratio is -6.59. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MCCHRLS-B.BO's ROE of -1.38%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MCCHRLS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MCCHRLS-B.BO's competition here
KOLTEPATIL.BO vs ARIHANT.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, ARIHANT.NS has a market cap of 8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while ARIHANT.NS trades at ₹916.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas ARIHANT.NS's P/E ratio is 14.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANT.NS's ROE of +0.23%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANT.NS's competition here
KOLTEPATIL.BO vs MODIS.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MODIS.BO has a market cap of 7.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MODIS.BO trades at ₹404.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MODIS.BO's P/E ratio is 31.24. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MODIS.BO's ROE of +0.35%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MODIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MODIS.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OSWALAGRO.BO has a market cap of 6.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OSWALAGRO.BO trades at ₹49.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OSWALAGRO.BO's P/E ratio is 7.65. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OSWALAGRO.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OSWALAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, OSWALAGRO.NS has a market cap of 6.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while OSWALAGRO.NS trades at ₹48.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas OSWALAGRO.NS's P/E ratio is 7.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OSWALAGRO.NS's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OSWALAGRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.NS's competition here
KOLTEPATIL.BO vs HAZOOR.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, HAZOOR.BO has a market cap of 6.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while HAZOOR.BO trades at ₹27.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas HAZOOR.BO's P/E ratio is 29.87. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HAZOOR.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to HAZOOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HAZOOR.BO's competition here
KOLTEPATIL.BO vs GEECEE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GEECEE.BO has a market cap of 6.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GEECEE.BO trades at ₹296.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GEECEE.BO's P/E ratio is 28.19. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GEECEE.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GEECEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.BO's competition here
KOLTEPATIL.BO vs GEECEE.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, GEECEE.NS has a market cap of 6.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while GEECEE.NS trades at ₹296.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas GEECEE.NS's P/E ratio is 27.59. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GEECEE.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GEECEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.NS's competition here
KOLTEPATIL.BO vs PENINLAND.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PENINLAND.NS has a market cap of 5.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PENINLAND.NS trades at ₹16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PENINLAND.NS's P/E ratio is -8.84. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PENINLAND.NS's ROE of -0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.NS's competition here
KOLTEPATIL.BO vs PENINLAND.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PENINLAND.BO has a market cap of 5.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PENINLAND.BO trades at ₹17.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PENINLAND.BO's P/E ratio is -8.81. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PENINLAND.BO's ROE of -0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.BO's competition here
KOLTEPATIL.BO vs NILASPACES.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NILASPACES.NS has a market cap of 5.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NILASPACES.NS trades at ₹13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NILASPACES.NS's P/E ratio is 22.30. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILASPACES.NS's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILASPACES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.NS's competition here
KOLTEPATIL.BO vs NILASPACES.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NILASPACES.BO has a market cap of 5.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NILASPACES.BO trades at ₹13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NILASPACES.BO's P/E ratio is 22.21. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILASPACES.BO's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILASPACES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.BO's competition here
KOLTEPATIL.BO vs PANSARI.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PANSARI.NS has a market cap of 5.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PANSARI.NS trades at ₹316.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PANSARI.NS's P/E ratio is 30.35. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PANSARI.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PANSARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PANSARI.NS's competition here
KOLTEPATIL.BO vs SBGLP.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SBGLP.BO has a market cap of 4.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SBGLP.BO trades at ₹26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SBGLP.BO's P/E ratio is 15.88. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SBGLP.BO's ROE of +0.44%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SBGLP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.BO's competition here
KOLTEPATIL.BO vs SBGLP.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SBGLP.NS has a market cap of 4.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SBGLP.NS trades at ₹27.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SBGLP.NS's P/E ratio is 15.41. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SBGLP.NS's ROE of +0.44%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SBGLP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.NS's competition here
KOLTEPATIL.BO vs YOGI.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, YOGI.BO has a market cap of 4.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while YOGI.BO trades at ₹160.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas YOGI.BO's P/E ratio is 35.40. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to YOGI.BO's ROE of +0.18%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to YOGI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YOGI.BO's competition here
KOLTEPATIL.BO vs EMAMIREAL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, EMAMIREAL.BO has a market cap of 4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while EMAMIREAL.BO trades at ₹95.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas EMAMIREAL.BO's P/E ratio is -1.84. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to EMAMIREAL.BO's ROE of +1.53%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to EMAMIREAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.BO's competition here
KOLTEPATIL.BO vs EMAMIREAL.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, EMAMIREAL.NS has a market cap of 3.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while EMAMIREAL.NS trades at ₹94.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas EMAMIREAL.NS's P/E ratio is -1.80. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to EMAMIREAL.NS's ROE of +1.53%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to EMAMIREAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.NS's competition here
KOLTEPATIL.BO vs PARSVNATH.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PARSVNATH.BO has a market cap of 3.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PARSVNATH.BO trades at ₹7.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PARSVNATH.BO's P/E ratio is -1.08. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PARSVNATH.BO's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PARSVNATH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PARSVNATH.BO's competition here
KOLTEPATIL.BO vs RATNABHUMI.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RATNABHUMI.BO has a market cap of 3.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RATNABHUMI.BO trades at ₹254.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RATNABHUMI.BO's P/E ratio is 67.02. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RATNABHUMI.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RATNABHUMI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RATNABHUMI.BO's competition here
KOLTEPATIL.BO vs PARSVNATH.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, PARSVNATH.NS has a market cap of 3.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while PARSVNATH.NS trades at ₹7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas PARSVNATH.NS's P/E ratio is -0.78. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PARSVNATH.NS's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PARSVNATH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PARSVNATH.NS's competition here
KOLTEPATIL.BO vs NILAINFRA.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NILAINFRA.BO has a market cap of 3.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NILAINFRA.BO trades at ₹8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NILAINFRA.BO's P/E ratio is 14.57. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILAINFRA.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILAINFRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILAINFRA.BO's competition here
KOLTEPATIL.BO vs NILAINFRA.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, NILAINFRA.NS has a market cap of 3.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while NILAINFRA.NS trades at ₹8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas NILAINFRA.NS's P/E ratio is 14.47. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILAINFRA.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILAINFRA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILAINFRA.NS's competition here
KOLTEPATIL.BO vs SVGLOBAL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SVGLOBAL.BO has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SVGLOBAL.BO trades at ₹150.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SVGLOBAL.BO's P/E ratio is 46.70. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SVGLOBAL.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SVGLOBAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SVGLOBAL.BO's competition here
KOLTEPATIL.BO vs MERCANTILE.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, MERCANTILE.BO has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while MERCANTILE.BO trades at ₹23.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas MERCANTILE.BO's P/E ratio is 21.38. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MERCANTILE.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MERCANTILE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MERCANTILE.BO's competition here
KOLTEPATIL.BO vs RVHL.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RVHL.NS has a market cap of 2.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RVHL.NS trades at ₹42.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RVHL.NS's P/E ratio is 5.05. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RVHL.NS's ROE of +0.20%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RVHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RVHL.NS's competition here
KOLTEPATIL.BO vs RVHL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, RVHL.BO has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while RVHL.BO trades at ₹43.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas RVHL.BO's P/E ratio is 4.94. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RVHL.BO's ROE of +0.20%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RVHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RVHL.BO's competition here
KOLTEPATIL.BO vs KBCGLOBAL.BO Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, KBCGLOBAL.BO has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while KBCGLOBAL.BO trades at ₹0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas KBCGLOBAL.BO's P/E ratio is -8.00. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KBCGLOBAL.BO's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KBCGLOBAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KBCGLOBAL.BO's competition here
KOLTEPATIL.BO vs SUMIT.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, SUMIT.NS has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while SUMIT.NS trades at ₹53.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas SUMIT.NS's P/E ratio is 25.64. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUMIT.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SUMIT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUMIT.NS's competition here
KOLTEPATIL.BO vs KBCGLOBAL.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, KBCGLOBAL.NS has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while KBCGLOBAL.NS trades at ₹0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas KBCGLOBAL.NS's P/E ratio is -9.40. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KBCGLOBAL.NS's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KBCGLOBAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KBCGLOBAL.NS's competition here
KOLTEPATIL.BO vs YAARI.NS Comparison May 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 34.5B. In comparison, YAARI.NS has a market cap of 2.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹395.35, while YAARI.NS trades at ₹21.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 66.27, whereas YAARI.NS's P/E ratio is -3.23. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to YAARI.NS's ROE of -0.12%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to YAARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YAARI.NS's competition here